• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Clinical management and viral genomic diversity analysis of a child's influenza A(H1N1)pdm09 infection in the context of a severe combined immunodefic

tetano

Editor, Senior Moderator
Antiviral Res. 2018 Oct 10. pii: S0166-3542(18)30307-3. doi: 10.1016/j.antiviral.2018.10.009. [Epub ahead of print]
[h=1]Clinical management and viral genomic diversity analysis of a child's influenza A(H1N1)pdm09 infection in the context of a severe combined immunodeficiency.[/h] Pichon M[SUP]1[/SUP], Picard C[SUP]1[/SUP], Simon B[SUP]2[/SUP], Gaymard A[SUP]1[/SUP], Renard C[SUP]3[/SUP], Massenavette B[SUP]4[/SUP], Malcus C[SUP]5[/SUP], Monneret G[SUP]5[/SUP], Morfin-Sherpa F[SUP]1[/SUP], Valette M[SUP]1[/SUP], Javouhey E[SUP]4[/SUP], Millat G[SUP]6[/SUP], Lina B[SUP]1[/SUP], Josset L[SUP]1[/SUP], Escuret V[SUP]7[/SUP].
[h=3]Author information[/h]

[h=3]Abstract[/h] [h=4]INTRODUCTION:[/h] A child with severe combined immunodeficiency (SCID) had an influenza A(H1N1)pdm09 infection with viral excretion longer than 6 months, during 2013-2014 influenza season, despite cord blood transplantation and antiviral treatments.
[h=4]METHODS:[/h] Conventional real-time RT-PCR methods were used to estimate viral load and to detect the presence of the common N1 neuraminidase (NA) H275Y substitution responsible for oseltamivir resistance. Next-generation sequencing (NGS) of influenza viruses was performed retrospectively to characterize viral quasispecies in specimens.
[h=4]RESULTS:[/h] The patient was first treated with oral oseltamivir, leading to detection of low-levels of NA-H275Y substitution. Concomitant cord blood cell transplantation, intravenous administration of zanamivir and immunoglobulins led to an increase in white blood cells and influenza viral load decrease. A viral rebound occurred as soon as the antiviral treatment was discontinued. Eventually, influenza viral load was negated with immune reconstitution. NGS found influenza quasispecies harboring NA-E119A substitution (10.3%). Moreover, NGS showed that viral genomic diversity evolved under antiviral treatment and immune status.
[h=4]CONCLUSIONS:[/h] Conventional virological techniques were sufficient for influenza infection follow-up but NGS performances allowed characterization of viral variants evolution in this specific case of prolonged influenza virus infection. New and efficient treatments against influenza in immunocompromised patients are needed.
Copyright ? 2018. Published by Elsevier B.V.


[h=4]KEYWORDS:[/h] Influenza A(H1N1)pdm09 virus; Intravenous zanamivir; NA-E119A substitution; NA-H275Y substitution; Next-generation sequencing; Oseltamivir resistance

PMID: 30315875 DOI: 10.1016/j.antiviral.2018.10.009
 
Back
Top